Results 211 to 220 of about 11,153,449 (375)
Asset Sales to Private Equity Funds - Shareholder Value Maximization on the Sell-Side? [PDF]
, 2009 David Oesch, Stefan Morkoetter
openalex +1 more source
Clinical Pharmacology in Drug Development, EarlyView.Abstract Imlunestrant (LY3484356) is a next‐generation orally bioavailable selective estrogen receptor degrader being investigated for the treatment of estrogen receptor–positive advanced breast and endometrial cancers. This Phase 1, open‐label, 2‐part study evaluated the disposition and absolute bioavailability of [14C]‐imlunestrant in 16 US‐based ...
Amita Datta‐Mannan +6 more
wiley +1 more source
One Share - One Vote: The Theory [PDF]
The impact of separating cash flow and votes depends on the ownership structure. In widely held firms, one share - one vote is in general not optimal. While it ensures an efficient outcome in bidding contests, dual-class shares mitigate the free-rider ...
Burkart, Mike, Lee, Samuel
core
Clinical Pharmacology &Therapeutics, EarlyView.Congenital thrombotic thrombocytopenic purpura (cTTP) is an ultra‐rare, potentially life‐threatening condition caused by a deficiency of the blood enzyme ADAMTS13. Until now, ADAMTS13 replacement has been achieved with infusions of plasma or plasma‐based therapies (PBT).
Munjal Patel +11 more
wiley +1 more source
Exposure‐Response Relationships for Axatilimab in Patients with Chronic Graft‐Versus‐Host Disease
Clinical Pharmacology &Therapeutics, EarlyView.Axatilimab, a high‐affinity humanized monoclonal antibody that targets colony‐stimulating factor 1 receptor, is approved for the treatment of chronic graft‐versus‐host disease (cGVHD). Here, we describe the exposure‐response relationships for efficacy and safety in patients with cGVHD who received axatilimab.
Yan‐ou Yang +7 more
wiley +1 more source
Risk seeking or averse, how do analyst coverage and firm visits motivate managers? [PDF]
PLoS OneLiu H, Guo X, Sheng D.
europepmc +1 more source
Clinical Pharmacology &Therapeutics, EarlyView.The US Food and Drug Administration 2024 guidance prefers regression analysis over categorical analysis for pharmacokinetic data for studies that assess pharmacokinetics in patients with impaired renal functions. The objective of this study was to compare these two statistical methods for pharmacokinetic data analysis of renal impairment studies ...
Gerald Chun‐To So +7 more
wiley +1 more source
Innovation and valuation of Chinese born-global firms. [PDF]
PLoS OneCai R, Zhang C, Xie Y, Kim M.
europepmc +1 more source